Biweekly Docetaxel in Patients With Metastatic Breast Cancer.
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
There is clinical benefit of docetaxel administered to patients who have progressed to 3 or
more lines of chemotherapy including prior exposure to paclitaxel or docetaxel; using
docetaxel in metastatic stage breast cancer previously exposed to taxanes equal therapeutic
responses are obtained that it never received taxanes.